AstraZeneca PLC (AZN.L)
An experimental breast cancer drug being developed by British drugmaker AstraZeneca and Japan's Daiichi Sankyo's met its main goal in a mid-stage study, bolstering their position in a highly competitive oncology market.
* Plan to seek FDA approval in second half of year (Adds details on regulatory submission, analyst comment on potential sales)
British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.
May 2 British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.
April 26 European shares finished higher on Friday as some strong earnings and data showing U.S. economic growth in the first-quarter beat expectations helped cut losses from earlier in the session.
AstraZeneca Plc beat first-quarter sales and earnings expectations on Friday as the British drugmaker benefited from a push into cancer drugs and emerging markets including China.
* Current China growth rate not sustainable, still bullish (Adds executive comment, updates shares)
April 26 Britain's FTSE 100 index is seen opening 4 points higher at 7,438 on Friday, according to financial bookmakers, while FTSE 100 futures were up 0.07 percent ahead of the cash market open.
April 26 British drugmaker AstraZeneca Plc's first-quarter product sales beat analysts' expectations on Friday, benefiting from higher demand for its cancer medicines.
The following Spanish stocks may be affected by newspaper reports and other factors on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: